Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 980
Filter
1.
J Drugs Dermatol ; 23(5): 332-337, 2024 May 01.
Article in English | MEDLINE | ID: mdl-38709699

ABSTRACT

BACKGROUND: Peer-reviewed, clinical studies measuring the efficacy and usability of skin care products enhance their integrity and may guide experts in the field in providing recommendations. A single-blind, prospective clinical study was designed to assess the subject satisfaction, clinical benefit, and safety of three photodynamic topical formulations referred to as MMSRepose (MMSRep), MMSRevive (MMSRev), and MMSBalance (MMSB).  Methods: Thirteen male and female patients (mean age 49 +/- 17.8 years) applied one of the three topical serums twice daily over a period of 12 weeks. Subjects returned for photography, and blinded investigator evaluation of rhytides (fine lines) and dyspigmentation were measured on a 6- and 4-point scale, respectively. Patient-perceived efficacy of multiple clinical outcomes was measured on a 5-point scale.  Results: 100% of subjects reported at least a 1-grade improvement in global aesthetic at the conclusion of the study. Investigator assessment revealed an overall 53.3% decrease in rhytides, correlating to a mean point reduction from 1.65 +/- 0.77 to 0.77 +/- 0.53 (P<0.001) from baseline to week 12. Investigator assessment of dyspigmentation revealed a 62.7% decrease, correlating to a mean point reduction of 1.85 +/- 0.68 from week 1 to 0.69 +/- 0.48 at week 12 (P<0.001). CONCLUSION: Photodynamic serums demonstrate clinical efficacy in skin rejuvenation and high user satisfaction. There were no serious adverse events. This study is limited by the inability to randomize to placebo due to the small sample size, as subject retention was heavily impacted by the SARS-CoV-2 pandemic. Future studies may be indicated to undergo comparison with a larger cohort.  J Drugs Dermatol. 2024;23(5):332-337. doi:10.36849/JDD.7167.


Subject(s)
Patient Satisfaction , Photochemotherapy , Skin Aging , Humans , Prospective Studies , Female , Male , Middle Aged , Photochemotherapy/methods , Photochemotherapy/adverse effects , Skin Aging/drug effects , Single-Blind Method , Adult , Aged , Treatment Outcome , Photosensitizing Agents/administration & dosage , Photosensitizing Agents/adverse effects , Skin Care/methods , Administration, Cutaneous , Rejuvenation
2.
J Med Case Rep ; 18(1): 264, 2024 May 30.
Article in English | MEDLINE | ID: mdl-38811941

ABSTRACT

BACKGROUND: Although 5-aminolevulinic acid is useful for the photodynamic diagnosis of bladder tumors, it often causes severe intraoperative hypotension. We report a case of postoperative cardiac arrest in addition to severe intraoperative hypotension, probably owing to the use of 5-aminolevulinic acid. CASE PRESENTATION: An 81-year-old Japanese man was scheduled to undergo transurethral resection of bladder tumor. The patient took 5-aminolevulinic acid orally 2 hours before entering the operating room. After the induction of anesthesia, his blood pressure decreased to 47/33 mmHg. The patient's hypotension did not improve even after noradrenaline was administered. After awakening from anesthesia, the patient's systolic blood pressure increased to approximately 100 mmHg, but approximately 5 hours after returning to the ward, cardiac arrest occurred for approximately 12 seconds. CONCLUSION: We experienced a case of postoperative cardiac arrest in a patient, probably owing to the use of 5-aminolevulinic acid. Although the cause of cardiac arrest is unknown, perioperative hemodynamic management must be carefully performed in patients taking 5-aminolevulinic acid.


Subject(s)
Aminolevulinic Acid , Heart Arrest , Hypotension , Postoperative Complications , Urinary Bladder Neoplasms , Humans , Male , Aminolevulinic Acid/adverse effects , Hypotension/etiology , Hypotension/chemically induced , Aged, 80 and over , Heart Arrest/etiology , Heart Arrest/chemically induced , Urinary Bladder Neoplasms/surgery , Photosensitizing Agents/adverse effects , Photosensitizing Agents/therapeutic use , Intraoperative Complications/chemically induced
3.
Acta Derm Venereol ; 104: adv19459, 2024 Apr 10.
Article in English | MEDLINE | ID: mdl-38596905

ABSTRACT

Simulated daylight photodynamic therapy is a relatively new and potentially less painful alternative to conventional red light photodynamic therapy for actinic keratosis. Qualitative research exploring patient experiences of pain and skin reactions during these treatments is scarce. To address this, semi-structured interviews were conducted of 10 patients aged 60-81 years with symmetrically distributed actinic keratoses 4 weeks after split-face treatment with conventional red light photodynamic therapy and simulated daylight photodynamic therapy. The participants were recruited from an ongoing clinical randomized trial. Interviews (median length 35 min) were conducted between June 2022 and January 2023, audio-recorded, transcribed verbatim, and analysed qualitatively using content analysis, as described by Graneheim and Lundman. Participants reported that conventional red light photodynamic therapy was very painful during illumination and transiently painful in the post-treatment period, while simulated daylight photodynamic therapy was almost painless during illumination and led to minor post-treatment pain. Also, skin reactions were more intense and longer-lasting with conventional red light photodynamic therapy than with simulated daylight photodynamic therapy. Most participants expressed a treatment preference for simulated daylight photodynamic therapy but had reservations about its unestablished long-term effectiveness. This study underscores the considerable pain associated with conventional red light photodynamic therapy, and the pivotal importance of shared decision-making when selecting the most appropriate treatment.


Subject(s)
Keratosis, Actinic , Photochemotherapy , Humans , Aminolevulinic Acid , Keratosis, Actinic/diagnosis , Keratosis, Actinic/drug therapy , Pain/diagnosis , Pain/etiology , Pain/drug therapy , Photochemotherapy/adverse effects , Photosensitizing Agents/adverse effects , Red Light , Treatment Outcome
4.
Medicine (Baltimore) ; 103(16): e37855, 2024 Apr 19.
Article in English | MEDLINE | ID: mdl-38640292

ABSTRACT

RATIONALE: The bullous variant of central serous chorioretinopathy (CSC) is a severe form of chronic CSC. Patients with the bullous variant of CSC have an increased risk of experiencing multiple pigment epithelial detachments (PEDs) and retinal pigment epithelium (RPE) tears. Photodynamic therapy (PDT) is a treatment for the bullous variant of CSC. RPE tear is a possible postoperative complication of PDT for eyes with PEDs. To our knowledge, no cases of giant RPE tears following PDT for the bullous variant of CSC have been reported previously. This case report presents the first instance of a giant RPE tear after half-time PDT for the bullous variant of CSC, accompanied by a series of images depicting the tear development. PATIENT CONCERNS: A 63-year-old male patient presented with rapidly deteriorating vision in his left eye over a 3-month period. He also reported a previous episode of vision loss in his right eye 2 years prior. Best-corrected visual acuity (BCVA) in the left eye was 0.2. DIAGNOSIS: The right eye was diagnosed with chronic non-bullous CSC, while the left eye was diagnosed with the bullous variant of CSC with a large PED. INTERVENTIONS: Half-time PDT was administered to the left eye. OUTCOMES: One month after half-time PDT, a giant RPE tear exceeding 3 clock-hours in size was confirmed in the lower temporal quadrant of the left eye. Three months after the initial half-time PDT, a second half-time PDT was performed owing to recurrent retinal detachment. Two months after the second half-time PDT, the retinal detachment resolved, and BCVA improved to 0.4, 6 months after the second half-time PDT. LESSONS: In cases where the bullous variant of CSC is complicated by extensive PED, clinicians should consider the potential development of a giant RPE tear as a treatment complication.


Subject(s)
Central Serous Chorioretinopathy , Photochemotherapy , Retinal Detachment , Retinal Perforations , Male , Humans , Middle Aged , Central Serous Chorioretinopathy/chemically induced , Central Serous Chorioretinopathy/drug therapy , Central Serous Chorioretinopathy/complications , Retinal Detachment/etiology , Photochemotherapy/adverse effects , Photochemotherapy/methods , Visual Acuity , Retinal Perforations/surgery , Retinal Perforations/complications , Fluorescein Angiography , Retinal Pigments/therapeutic use , Tomography, Optical Coherence , Photosensitizing Agents/adverse effects , Retrospective Studies
5.
Am J Clin Dermatol ; 25(3): 391-405, 2024 May.
Article in English | MEDLINE | ID: mdl-38351246

ABSTRACT

Field cancerization theory highlights that the skin surrounding actinic keratoses (AK) is also at increased risk for possible malignant transformation; thus, field-directed treatments may both reduce the risk of AK recurrence and potentially reduce the risk of development of cutaneous squamous cell carcinoma (cSCC). Photodynamic therapy (PDT) with either aminolevulinic acid (ALA) or methylaminolevulinate (MAL), as well as topical treatments such as 5-fluorouracil (5-FU), diclofenac gel, piroxicam, imiquimod, and ingenol mebutate, have all shown higher efficacy than vehicle treatments. PDT is widely recognized for its high efficacy; however, concerns for associated pain have driven new studies to begin using alternative illumination and pretreatment techniques, including lasers. Among topical treatments, a combination of 5-FU and salicylic acid (5-FU-SA) has shown to be the most effective but also causes the most adverse reactions. Tirbanibulin, a new topical agent approved for use in 2020, boasts a favorable safety profile in comparison with imiquimod, 5-FU, and diclofenac. Meanwhile, ingenol mebutate is no longer recommended for the treatment of AKs due to concerns for increased risk of cSCC development. Moving forward, an increasing number of studies push for standardization of outcome measures to better predict risk of future cSCC and use of more effective measures of cost to better guide patients. Here, we present an updated and comprehensive narrative review both confirming the efficacy of previously mentioned therapies as well as highlighting new approaches to PDT and discussing the use of lasers and novel topical treatments for treatment of AK.


Subject(s)
Carcinoma, Squamous Cell , Keratosis, Actinic , Photochemotherapy , Skin Neoplasms , Humans , Keratosis, Actinic/therapy , Keratosis, Actinic/drug therapy , Photochemotherapy/methods , Photochemotherapy/adverse effects , Skin Neoplasms/prevention & control , Skin Neoplasms/etiology , Skin Neoplasms/therapy , Carcinoma, Squamous Cell/prevention & control , Carcinoma, Squamous Cell/etiology , Carcinoma, Squamous Cell/therapy , Cell Transformation, Neoplastic , Administration, Cutaneous , Treatment Outcome , Antineoplastic Agents/adverse effects , Antineoplastic Agents/administration & dosage , Antineoplastic Agents/therapeutic use , Photosensitizing Agents/administration & dosage , Photosensitizing Agents/adverse effects , Photosensitizing Agents/therapeutic use , Laser Therapy/methods
7.
Photodiagnosis Photodyn Ther ; 45: 103925, 2024 Feb.
Article in English | MEDLINE | ID: mdl-38070631

ABSTRACT

This study provides an overview of the effectiveness and safety of PDT for the treatment of HPV-associated precancerous cervical conditions and contains recent findings from relevant research studies. A comprehensive literature search of MEDLINE/PubMed, Cochrane Central Library, and Google Scholar was conducted, including analytic epidemiological studies, and 11 papers were included. The narrative synthesis approach was used to summarize the results of the included studies. Studies were critically appraised using The Joanna Briggs Institute (JBI) tool for assessing the risk of bias. The results of the study demonstrate that CRR for HPV remission ranges from 66.7 % to 92.73 %, whereas for CIN1 it fluctuates from 57.1 % to 83.3 %. The frequency of recurrence of the disease ranged from 3.3 % to 8.9 % during the follow-up period of up to 2 years. Adverse events were observed in 8 (66 %) studies and the most common were cervical stenosis, abdominal pain, vaginal pain, and focal edema. Five types of topical and intravenous applications along with lasers of various wavelengths and intensities were mostly used. However, all studies demonstrated relatively similar results. According to the results, PDT has demonstrated favorable outcomes, but no impressive effect on the treatment of CIN. It should be emphasized, that the effectiveness of PDT for the treatment of HPV-associated CIN may vary depending on some variables, including the kind of PDT agent used, the dosage, duration and frequency of PDT administration, the severity and location of the lesions, and the host immunological response.


Subject(s)
Papillomavirus Infections , Photochemotherapy , Precancerous Conditions , Uterine Cervical Dysplasia , Uterine Cervical Neoplasms , Female , Humans , Cervix Uteri , Human Papillomavirus Viruses , Papillomavirus Infections/drug therapy , Photochemotherapy/methods , Photosensitizing Agents/adverse effects , Photosensitizing Agents/therapeutic use , Precancerous Conditions/drug therapy , Uterine Cervical Dysplasia/therapy , Uterine Cervical Neoplasms/therapy
8.
Retina ; 44(1): 56-62, 2024 Jan 01.
Article in English | MEDLINE | ID: mdl-37603591

ABSTRACT

PURPOSE: To describe the incidence, features, and clinical outcomes of photodynamic therapy-induced acute exudative maculopathy (PAEM) in circumscribed choroidal hemangioma. METHODS: Prospective series of 10 patients who underwent standard-fluence photodynamic therapy for circumscribed choroidal hemangioma. Best-corrected visual acuity in the Early Treatment Diabetic Retinopathy Score and swept-source optical coherence tomography were performed before PDT and 3 days and 1 month after PDT. Central retinal thickness, circumscribed choroidal hemangioma retinal thickness, and subretinal fluid were measured. Photodynamic therapy-induced acute exudative maculopathy was considered as an increase ≥50 µ m in subretinal fluid or intraretinal fluid or the appearance of fibrin 3 days after photodynamic therapy. RESULTS: Six men and four women were included; median age was 55 years (19-69 years). The incidence rate of PAEM was 7 of 10. Five PAEM patients showed an increase in intraretinal fluid, two in subretinal fluid, and one developed abundant fibrin. Median best-corrected visual acuity at baseline was 57.5 letters (5-76 letters) being stable at 1 month (64 letters; 5-80) ( P = 0.03). Median central retinal thickness increased from 516 µ m (262-1,265 µ m) to 664.5 µ m after 3 days and diminished to 245 µ m after 1 month (156-1,363) ( P ≤ 0.022). In 6 of 7 of PAEM, a complete resolution of the fluid was obtained. CONCLUSION: Photodynamic therapy-induced acute exudative maculopathy was frequent in circumscribed choroidal hemangioma, although a favorable prognosis was observed in most cases.


Subject(s)
Choroid Neoplasms , Hemangioma , Macular Degeneration , Photochemotherapy , Male , Humans , Female , Middle Aged , Photochemotherapy/adverse effects , Photochemotherapy/methods , Retina , Choroid Neoplasms/diagnosis , Choroid Neoplasms/drug therapy , Choroid Neoplasms/etiology , Hemangioma/diagnosis , Hemangioma/drug therapy , Tomography, Optical Coherence/methods , Macular Degeneration/drug therapy , Fibrin , Photosensitizing Agents/adverse effects , Treatment Outcome , Retrospective Studies , Fluorescein Angiography
9.
Photodiagnosis Photodyn Ther ; 45: 103838, 2024 Feb.
Article in English | MEDLINE | ID: mdl-37844787

ABSTRACT

INTRODUCTION: Photodynamic therapy (PDT) is a safe, non-mutagenic, and non-scarring treatment for actinic keratoses (AK). BACKGROUND: 'Painless' photodynamic therapy (p-PDT) is a regimen for AK that employs simultaneous aminolevulinate incubation and blue light illumination. The efficacy of p-PDT resembles that of traditional PDT, but detailed mechanisms of action for p-PDT are not well understood. METHODS: To characterize the inflammatory effects of the p-PDT procedure 48 h following treatment and determine the association of inflammation with precancer burden, we performed a retrospective cohort study of 104 patients with AK of face or scalp treated with p-PDT between 2017 and 2019. Patients self-reported their side effects 48 h following p-PDT and took photographs of their face and scalp. Photographs were edited to define seven anatomic regions, and erythema was scored by four investigators. RESULTS: Ninety-eight patients provided photographs suitable for erythema evaluation. Most patients experienced 2 or more side effects and some pain 48 h post-procedure. Females experienced more pain (p = 0.01) and side effects (p = 0.002) compared to males. AK burden was positively associated with post p-PDT erythema response (p < 0.0001) at all sites, but particularly in the temples (p = 0.002) and supralabial area (p = 0.009). DISCUSSION: This study confirms a strong clinical inflammatory response after p-PDT. Severity of inflammation is positively associated with AK tumor burden, suggesting that post-treatment inflammation may be a pre-requisite for p-PDT efficacy. Interestingly, the results also identify certain gender-related differences in the severity of side effects experienced by patients post-PDT.


Subject(s)
Keratosis, Actinic , Photochemotherapy , Female , Male , Humans , Keratosis, Actinic/drug therapy , Retrospective Studies , Photochemotherapy/methods , Photosensitizing Agents/adverse effects , Scalp , Inflammation/drug therapy , Pain , Erythema
10.
Photodiagnosis Photodyn Ther ; 45: 103871, 2024 Feb.
Article in English | MEDLINE | ID: mdl-37935343

ABSTRACT

Rosacea is a chronic and inflammatory skin condition, with relapses being a common characteristic. Its treatments are based on cosmetics, drugs, and the application of procedures based on high-powered light. Photodynamic Cosmetic Therapy (PCT) combines light, a photosensitizer (PS), and molecular oxygen present in tissues, generating photochemical reactions capable of causing tissue and vascular destruction, stimulating tissue repair. We report a case with an adverse effect caused by applying PCT, using 2 % 5-aminolevulinic acid (ALA 2 %), and irradiated with amber LED light associated with infrared radiation for the control of rosacea. A patient with subtype II rosacea underwent PCT treatment of 3 sessions at 21-day intervals, being evaluated using photographic images and Wood's lamp. In the first session of the therapy, an exacerbated inflammatory process was observed. Such an adverse event is estimated to be as a result of the patient using ointment containing corticosteroids for a short period. With the use of medications, it was possible to recover the appearance of the skin thoroughly, and after 21 days, the treatment sessions were performed again. Despite the complication that affected the patient in this study, positive effects were found after the pharmacological therapeutic measures were adopted.


Subject(s)
Photochemotherapy , Rosacea , Humans , Photochemotherapy/methods , Photosensitizing Agents/adverse effects , Rosacea/drug therapy , Skin , Aminolevulinic Acid/adverse effects
11.
J Am Acad Dermatol ; 89(6): 1141-1148, 2023 12.
Article in English | MEDLINE | ID: mdl-37558093

ABSTRACT

BACKGROUND: Modified 5-aminolevulinic acid photodynamic therapy (M-PDT) and isotretinoin (ISO) are effective treatments for moderate to severe acne vulgaris. OBJECTIVE: To evaluate the efficacy and adverse effects of M-PDT and ISO for moderate to severe acne vulgaris. METHODS: A multicenter, randomized clinical trial was conducted with participants randomly assigned to the M-PDT group (up to 5 weekly sessions following manual comedone extraction) or the ISO group (oral ISO, 0.5 mg/kg/d for 6 months) and followed up to 6-months after therapy. RESULTS: A total of 152 patients were allocated. The overall effective rates in the M-PDT group were significantly higher than the ISO group at 1 month (67.74% vs 10.26%), whereas the opposite was the case 1 month after treatment (75.81% vs 97.44%). Time to achieve 50% lesion improvement in the M-PDT group was significantly less than the ISO group (1 vs 8 weeks). Overall, 70.67% of the ISO group patients experienced systemic side effects such as hepatotoxicity, whereas side effects were skin-limited in the M-PDT group. LIMITATIONS: Limitations of this study included relatively low numbers of participants and high withdrawal rate. CONCLUSION: M-PDT offers a more rapid onset of improvement, comparable overall efficacy, good tolerability, and comparable durability of response compared with ISO.


Subject(s)
Acne Vulgaris , Photochemotherapy , Humans , Acne Vulgaris/drug therapy , Aminolevulinic Acid/adverse effects , Isotretinoin/adverse effects , Photochemotherapy/adverse effects , Photosensitizing Agents/adverse effects , Prospective Studies , Treatment Outcome
12.
Photodiagnosis Photodyn Ther ; 43: 103707, 2023 Sep.
Article in English | MEDLINE | ID: mdl-37451655

ABSTRACT

BACKGROUND: The efficacy of photodynamic diagnosis using 5-aminolevulinic acid during transurethral resection of bladder tumors has been demonstrated, albeit with limited information regarding its side effects. This study aimed to clarify the impact of oral 5-aminolevulinic acid on perioperative nausea and vomiting (NV) for the first time in a real-world clinical practice setting. METHODS: Patients who underwent transurethral surgery at Kagawa University between April 2017 and March 2020 were included. Perioperative NV and antiemetic use status were prospectively assessed and compared between the patients who received oral 5-aminolevulinic acid and those who did not. Additionally, univariate and multivariate analyses were performed for predicting postoperative nausea and vomiting. RESULTS: Of 214 patients, 74 (34.6%) received oral 5-aminolevulinic acid preoperatively. The proportions of preoperative NV and antiemetic use in the patients who received 5-aminolevulinic acid were 9.5% and 4.1%, respectively, and higher than in those who did not (0% and 0%; P < 0.01 and P = 0.04, respectively). Postoperative NV (25.7%) and antiemetics use (8.0%) ratios in the patients who received 5-aminolevulinic acid were significantly different from those in the non-users group (3.6% and 2.1%, P < 0.01 and P < 0.01, respectively). Although no differences in risk factors were found for postoperative NV between the two groups, multivariate analyses indicated 5-aminolevulinic acid use as an independent predictive factor for postoperative NV (odds ratio, 11.5; 95% confidence interval, 3.98-33.3; P < 0.01). CONCLUSIONS: Our study clearly showed that oral administration of 5-aminolevulinic acid was associated with perioperative NV even without risk factors, highlighting the need for addressing its application.


Subject(s)
Antiemetics , Photochemotherapy , Urinary Bladder Neoplasms , Humans , Aminolevulinic Acid/adverse effects , Antiemetics/therapeutic use , Photosensitizing Agents/adverse effects , Transurethral Resection of Bladder , Photochemotherapy/methods , Urinary Bladder Neoplasms/pathology , Vomiting/chemically induced , Vomiting/drug therapy , Nausea/chemically induced , Nausea/drug therapy , Administration, Oral
13.
Retina ; 43(11): 1988-1995, 2023 11 01.
Article in English | MEDLINE | ID: mdl-37343292

ABSTRACT

PURPOSE: To analyze the 2-year clinical outcomes after photodynamic therapy-induced acute exudative maculopathy (PAEM) in patients with chronic central serous chorioretinopathy. METHODS: Prospective observational study that included 64 eyes of 64 patients with chronic central serous chorioretinopathy who received half-fluence photodynamic therapy and had a 2-year follow-up. Patients were classified into two groups based on whether they had had PAEM at 3 days after treatment (PAEM+, n = 22; ≥50 µ m) increase in subretinal fluid or not (PAEM-, n = 42). Best-corrected visual acuity and subretinal fluid changes evaluated with optical coherence tomography were registered at 3 days, 1 month, 3 months, 1 year, and 2 years after photodynamic therapy. The number of recurrences, the appearance of outer retinal atrophy, and choroidal neovascularization were analyzed. RESULTS: Best-corrected visual acuity was 75.9 ± 13.6 (20/32) and 82.0 ± 11.0 letters (20/25) at 2 years in the PAEM+ and PAEM- groups, respectively ( P = 0.055). There were no differences in the best-corrected visual acuity change (4.2 ± 7.7 vs. 3.3 ± 7.1 letters; P = 0.654) and the subretinal fluid decrease (-117.3 ± 74.2 vs. -138.5 ± 83.6 µ m; P = 0.323) at 2 years between patients with and without PAEM. No differences in the number of recurrences ( P = 0.267), the appearance of choroidal neovascularization ( P = 0.155), or outer retinal atrophy ( P = 0.273) between both groups were noted. CONCLUSION: Patients with chronic central serous chorioretinopathy with and without PAEM presented similar results at 2 years in best-corrected visual acuity gain, subretinal fluid reduction, and complication rate.


Subject(s)
Central Serous Chorioretinopathy , Choroidal Neovascularization , Macular Degeneration , Photochemotherapy , Humans , Atrophy/pathology , Central Serous Chorioretinopathy/diagnosis , Central Serous Chorioretinopathy/drug therapy , Central Serous Chorioretinopathy/pathology , Choroidal Neovascularization/drug therapy , Chronic Disease , Fluorescein Angiography , Macular Degeneration/drug therapy , Photochemotherapy/methods , Photosensitizing Agents/adverse effects , Retina/pathology , Retrospective Studies , Tomography, Optical Coherence , Treatment Outcome , Visual Acuity
14.
J Am Acad Dermatol ; 89(4): 711-718, 2023 10.
Article in English | MEDLINE | ID: mdl-37356626

ABSTRACT

BACKGROUND: 5-Aminolevulinic acid photodynamic therapy (ALA-PDT) showed potential to treat rosacea according to recent studies; however, a lack of clinical evidence and unclear adverse effects limit its use. OBJECTIVE: To compare the effect of ALA-PDT vs minocycline on rosacea. METHODS: In this single-center, randomized, evaluator-blind, controlled study, patients with moderate-to-severe rosacea were allocated to receive 3 to 5 sessions of ALA-PDT or 8 weeks of 100 mg daily minocycline treatment, followed by a 24-week follow-up. RESULTS: Of all the 44 randomized patients, 41 received complete treatment (ALA-PDT: 20 and minocycline: 21 patients). At the end of treatment, ALA-PDT showed noninferior improvement of papulopustular lesions and Rosacea-specific Quality of Life compared with minocycline (median reduction of lesion count: 19 vs 22, median change of Rosacea-specific Quality of Life score: 0.48 vs 0.53). The Clinician's Erythema Assessment success of ALA-PDT was lower than that of minocycline's (35% vs 67%). Demodex density and relapse rate were comparable in both groups. Erythema, mild pain, and exudation were the most common adverse reactions of ALA-PDT. LIMITATIONS: Limited sample size restricted us from drawing further conclusions. CONCLUSION: As minocycline does, ALA-PDT can improve rosacea mainly in papulopustular lesions and patients' quality of life, indicating a new option for rosacea.


Subject(s)
Photochemotherapy , Rosacea , Humans , Aminolevulinic Acid/adverse effects , Minocycline/adverse effects , Quality of Life , Photochemotherapy/adverse effects , Rosacea/drug therapy , Treatment Outcome , Photosensitizing Agents/adverse effects
15.
Exp Dermatol ; 32(9): 1371-1382, 2023 09.
Article in English | MEDLINE | ID: mdl-37157235

ABSTRACT

Hematoporphyrin monomethyl ether-photodynamic therapy (HMME-PDT) has achieved encouraging clinical outcomes in adult port-wine stain (PWS). Optimal treatment option for children with PWS was minimal. To compare whether the clinical effectiveness of HMME-PDT with the 5-min (fast) administration treatment regimen (FATR) was better than the 20-min (slow) administration treatment regimen (SATR) for PWS of children in vivo and in vitro. Thirty-four children with PWS were divided into two groups including FATR and SATR. The two groups received three times HMME-PDT, respectively. Treatment efficacy and safety were evaluated in vivo and in vitro. Erythema index (EI) was used to evaluate the clinical outcomes. Both FATR and SATR were effective and safe in children with PWS after HMME-PDT. There were significance differences between the two groups in reductions of EI after the second treatment (p < 0.001) and the third treatment (p < 0.001) with HMME-PDT. The serum HMME concentration reach the peak level at short time compare with SATR group. A significance increased superoxide levels were observed in FATR group compare to SATR groups in vitro (p < 0.05). Our study suggested that HMME-PDT was effective and safe for children with PWS, the therapy regimen with FATR was better in clinical efficacy than that of the SATR.


Subject(s)
Hemangioma, Capillary , Photochemotherapy , Port-Wine Stain , Child , Humans , East Asian People , Hemangioma, Capillary/drug therapy , Photochemotherapy/adverse effects , Photosensitizing Agents/adverse effects , Port-Wine Stain/drug therapy , Treatment Outcome
16.
J Drugs Dermatol ; 22(5): 481-485, 2023 May 01.
Article in English | MEDLINE | ID: mdl-37133481

ABSTRACT

BACKGROUND: To investigate the effectiveness, safety, patient satisfaction, and cosmetic outcome of Methyl Aminolevulinate-Photodynamic Therapy (MAL-PDT) following curettage in order to make recommendations for its use in dermatology practices. METHODS: A retrospective chart review of patients who received MAL-PDT following curettage for the indication of basal cell carcinoma (BCC) between 2009 and 2016 at a single private clinic in Ontario, Canada. Two hundred and seventy-eight patients with 352 BCC lesions were included, consisting of 44.2% males (n=123) and 55.8% females (n=155) with a mean age of 57.24 years. The primary outcome measurement consisted of the cure rate. Secondary outcome measurements included side effects, patient satisfaction, and cosmetic outcome, as reported in the medical charts. RESULTS: The overall cure rate was 90.3% (n=318). After controlling for age, sex, and lesion type, nasal lesions were approximately 2.82 (95% CI: 1.24-6.40, P=0.01) times more likely to experience a recurrence. 18.3% of patients (n=51) reported side effects, the most common being burning (n=19). Of those who expressed satisfaction, 100% (n=25) reported being happy. Of lesions with cosmetic data, 90.3% displayed a good response (n=149). CONCLUSION: MAL-PDT following curettage is an effective and safe treatment option for BCC lesions with a good cosmetic outcome and suggested high patient satisfaction. J Drugs Dermatol. 2023;22(5): doi:10.36849/JDD.7133.


Subject(s)
Carcinoma, Basal Cell , Photochemotherapy , Skin Neoplasms , Male , Female , Humans , Middle Aged , Photosensitizing Agents/adverse effects , Skin Neoplasms/drug therapy , Skin Neoplasms/surgery , Retrospective Studies , Treatment Outcome , Carcinoma, Basal Cell/drug therapy , Carcinoma, Basal Cell/etiology , Photochemotherapy/adverse effects , Aminolevulinic Acid , Ontario , Curettage
17.
Dermatol Surg ; 49(6): 544-551, 2023 06 01.
Article in English | MEDLINE | ID: mdl-37134239

ABSTRACT

BACKGROUND: Actinic keratoses (AKs) are common and some may evolve into squamous cell carcinoma. Photodynamic therapy (PDT), imiquimod, cryotherapy, and other methods have been reported to have good effects. However, which treatment is the most effective with the best cosmetic results and fewest complications is uncertain. OBJECTIVE: To evaluate which method has the best efficacy and cosmetic results with less adverse events and recurrence rate. MATERIALS AND METHODS: All relevant articles up to July 31, 2022 were searched from Cochrane, Embase, and PubMed databases. Extract and analyze the data of efficacy, cosmetic results, local reactions, and adverse effects. RESULTS: Twenty-nine articles with 3,,850 participants and 24,747 lesions were included. Quality of evidence was generally high. The efficacy of PDT was better in complete response (CR) (lesions CR; risk ratio (RR) 1.87; 95% confidence interval (CI) 1.55-1.87/patient CR; RR 3.07; 95% CI 2.07-4.56), overall preference, and cosmetic results. The time cumulative meta-analysis showed that the curative effect was gradually increasing before 2004, and then gradually stabilizing. Two groups showed no statistically significant differences in recurrence. CONCLUSION: Compared with other methods, PDT is significantly more effective for AK with excellent cosmetic results and reversible adverse effects.


Subject(s)
Keratosis, Actinic , Photochemotherapy , Humans , Keratosis, Actinic/drug therapy , Photosensitizing Agents/adverse effects , Aminolevulinic Acid/therapeutic use , Photochemotherapy/adverse effects , Photochemotherapy/methods , Randomized Controlled Trials as Topic , Treatment Outcome
18.
J Fr Ophtalmol ; 46(8): 921-928, 2023 Oct.
Article in English | MEDLINE | ID: mdl-37085363

ABSTRACT

PURPOSE: To evaluate the safety and efficacy of combined simultaneous photorefractive keratectomy (PRK) with collagen cross-linking (CXL) in keratoconus suspects (KCS). METHODS: This was a retrospective, non-randomized study of KCS patients who underwent combined simultaneous PRK with CXL. The efficacy, safety, refractive outcomes, and corneal wavefront aberration changes were assessed after the surgery and compared with existing preoperative data. RESULTS: Fifty-six eyes of 28 patients, including 20 females (71.4%), with a mean age of 30.92±4.09 years, were enrolled. The mean follow-up was 19.46±8.48 months (range: 7-35). At the conclusion of the study, mean uncorrected distance visual acuity LogMAR improved from 0.89±0.44 preoperatively to 0.04±0.09 postoperatively (P<0.001). In addition, a statistically significant corneal flattening was observed postoperatively, with a decrease in manifest refraction. A statistically significant increase was found in higher-order aberrations (P<0.001), horizontal coma (P<0.001), and spherical aberration (P<0.001) compared with preoperatively. Postoperatively, 41% exhibited refractive astigmatism of 0.50 diopter (D) or less; 83.8% showed 1.00 D or less. CONCLUSION: The results of our study indicate that combined simultaneous PRK with CXL can be a safe and effective method for treating refractive instability in KCS patients.


Subject(s)
Keratoconus , Photorefractive Keratectomy , Female , Humans , Adult , Photorefractive Keratectomy/adverse effects , Photorefractive Keratectomy/methods , Keratoconus/diagnosis , Keratoconus/drug therapy , Keratoconus/surgery , Visual Acuity , Photosensitizing Agents/adverse effects , Retrospective Studies , Riboflavin/adverse effects , Corneal Topography , Corneal Stroma/surgery , Collagen , Cross-Linking Reagents/adverse effects
19.
Photodiagnosis Photodyn Ther ; 41: 103294, 2023 Mar.
Article in English | MEDLINE | ID: mdl-36681259

ABSTRACT

BACKGROUND: Patient selection for transurethral resection of the bladder tumor using photodynamic diagnosis (PDD-TURBT) with oral 5-aminolevulinic acid (5-ALA) hydrochloride for non-muscle-invasive bladder cancer (NMIBC) is still unclear as to the best balance of risks (adverse events including hypotension) and benefits (reduction of intravesical recurrence). METHODS: This single-center retrospective study between April 2013 and March 2022, compared the intravesical recurrence-free survival between patients who underwent PDD-TURBT and WL-TURBT using propensity score matching. RESULTS: A total of 222 patients who underwent PDD-TURBT and 177 patients who underwent WL-TURBT for NMIBC were included. Propensity score matching was used to compare intravesical recurrence-free survival in 119 NMIBC patients in the both treatment groups. The intravesical recurrence-free survival within 500 days was significantly higher in the PDD-TURBT group than in the WL-TURBT group (P = 0.039; hazard ratio [HR] 0.48 [0.23-0.98]). Subgroup analysis showed that PDD-TURBT contributed to the reduction of short-term intravesical recurrence in patients aged < 75 years (P = 0.02; HR 0.22 [0.06-0.79]) and primary disease (P = 0.038; HR 0.35 [0.13-0.94]). Hypotension with a systolic blood pressure of < 80 mmHg was observed in 79 patients (35.6%) during PDD-TURBT surgery. In particular, age ≥75 years and general anesthesia were independent prognostic factors for predicting intraoperative hypotension. CONCLUSIONS: PDD-TURBT reduced short-term intravesical recurrence in NMIBC, whereas a higher frequency of hypotension was found in patients aged ≥ 75 years. These results suggest that the risks and benefits of PDD-TURBT are well balanced in younger patients (< 75 years) and those with primary disease.


Subject(s)
Non-Muscle Invasive Bladder Neoplasms , Photochemotherapy , Urinary Bladder Neoplasms , Humans , Photosensitizing Agents/adverse effects , Aminolevulinic Acid/adverse effects , Retrospective Studies , Photochemotherapy/methods , Urinary Bladder Neoplasms/diagnosis , Cystectomy/methods , Neoplasm Recurrence, Local/pathology , Neoplasm Invasiveness/pathology , Risk Assessment
20.
Photodiagnosis Photodyn Ther ; 40: 103190, 2022 Dec.
Article in English | MEDLINE | ID: mdl-36336323

ABSTRACT

BACKGROUND: Photodynamic therapy (PDT) is an effective method for treating actinic keratosis (AK) with pain during illumination representing the major side effect. The efficacy of two different cooling methods for pain relief in PDT of AK in the head region was compared. METHODS: Randomized, assessor-blinded, half side comparison study in 20 patients with symmetrically distributed AK on the head. Conventional PDT was performed on both halves of the scalp or face by applying 20% aminolevulinic acid cream (ALA) and subsequent illumination with incoherent red light. During illumination one side was cooled with a cold air blower (CAB) and the other with a standard fan (FAN) in a randomized fashion. Pain and skin temperature were recorded during and after PDT. The phototoxic skin reaction was evaluated up to seven days after PDT. The clearance rate of AK was assessed at 3 and 6 months after PDT. RESULTS: Mean pain (VASmean), maximum pain intensity (VASmax) and the mean skin temperature during PDT were significantly lower with CAB as compared to FAN (VASmean: 2.7 ± 1.4 vs. 3.7 ± 2.1, p = 0.003; VASmax: 3.8 ± 2.0 vs. 4.8 ± 2.5, p = 0.002; 26.8 ± 2.0 °C vs. 32.1 ± 1.7 °C; p=<0.001). The severity of the phototoxic skin reaction and the clearance rate of AK did not differ between the two cooling methods. CONCLUSION: Cooling with CAB during PDT has a greater analgesic effect than cooling with FAN. Patients with a lower skin temperature during illumination tended to experience less pain, however, this effect did not reach the level of statistical significance.


Subject(s)
Keratosis, Actinic , Photochemotherapy , Humans , Photochemotherapy/methods , Photosensitizing Agents/adverse effects , Keratosis, Actinic/drug therapy , Aminolevulinic Acid/adverse effects , Pain/etiology , Pain/chemically induced , Scalp , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...